About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn about Covance by Labcorp at www.Covance.com, and Labcorp at www.Labcorp.com, or follow us on LinkedIn and Twitter @Labcorp.
About Blood Centers of America
BCA is the nation’s largest blood supply network, providing over 50 percent of the nation’s blood supply. This national organization is comprised of over 60 independent community blood centers with a deep local commitment to the communities and patients they serve.
The BCA network encompasses over 500 collection and testing sites across the United States. In addition to meeting the transfusion needs of the communities they serve, BCA members provide human blood products, custom collections, cell processing, testing, storage, distribution, and other services to the therapeutic, diagnostic, and cell therapy industries. BCA members actively collect and provide critical raw materials for manufacturing of autologous and allogeneic cell-based therapies. Collectively, BCA’s members interact with nearly 3 million individual blood donors annually. Learn more about BCA at www.bca.coop or follow us on Linked In and Twitter @BCAbloodcenters.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to [our responses to and the expected future impacts of the COVID-19 pandemic,] scientific collaborations, customer contracts and relationships, the anticipated benefits of such collaboration and relationships, and the expected impact that the various collaborations and customer relationships may have on the Company’s financial results. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, [whether our [responses to the COVID-19 pandemic] will prove [effective/appropriate]], the impact of the COVID-19 pandemic on our business and financial condition as well as on general economic, business, and market conditions, the Company’s ability to establish and maintain strategic partnerships and other scientific collaborations, competitive actions in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, adverse actions of governmental and other third-party payers, patient safety issues, changes in testing guidelines or recommendations, and federal, state, and local governmental responses to the COVID-19 pandemic. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.
Contacts
Media: Christopher Allman-Bradshaw — 336-436-8263
[email protected]
Investors: Chas Cook— 336-436-5076
[email protected]